Nicole Lambert - Sep 21, 2021 Form 4 Insider Report for MYRIAD GENETICS INC (MYGN)

Signature
By: Nathan A. Smith For: Nicole Lambert
Stock symbol
MYGN
Transactions as of
Sep 21, 2021
Transactions value $
$0
Form type
4
Date filed
9/23/2021, 05:24 PM
Previous filing
Aug 30, 2021
Next filing
Sep 27, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MYGN Common Stock Award $0 +65.9K +51.85% $0.00 193K Sep 21, 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on October 8, 2020, subject to accomplishment of pre-determined performance metrics. On September 21, 2021, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024.

Remarks:

Ms. Lambert's title is Group President, Myriad Oncology, Myriad Women's Health and Myriad International.